Company Insights

PALI supplier relationships

Explore interactive graphBrowse insights index
PALI supplier relationship map

Palisade Bio (PALI) — supplier relationships, liabilities and what investors should underwrite

Palisade Bio is a clinical‑stage biopharmaceutical developer focused on oral, targeted PDE4 inhibitor prodrugs for inflammatory bowel disease; today the company monetizes through licensing, milestone/royalty structures and the prospect of future product sales, while operating with no product revenue and a balance sheet that reflects investor funding and partnership liabilities. For investors and operators evaluating counterparty risk, the practical picture is clear: Palisade outsources manufacturing, clinical supply and much of investor communications, and the economics of those relationships — contingent milestone obligations, CRO/CMO engagement and PR/IR vendors — are central to the company's path to value. Learn more about how we map supplier exposure at Null Exposure: https://nullexposure.com/

The supplier posture that underwrites PALI’s clinical runway

Palisade does not manufacture in‑house. The company relies on a network of CDMOs/CMOs for API and finished clinical supply, contracts CROs for trial oversight, and engages external investor‑relations and PR firms to distribute results and investor updates. This contracting posture creates concentration and operational dependency — the business is critically dependent on third parties for timely API supply and on external partners to execute clinical programs.

  • Geography signal: the company maintains agreements with foreign third parties, including suppliers in China, for clinical API supply.
  • Materiality signal: the company explicitly warns that insufficient API or raw materials could adversely impact operations.
  • Maturity and spend: manufacturing is outsourced and active at the clinical stage; public filings show six‑figure professional fees in 2024, a mid‑range supplier spend footprint for a clinical‑stage biotech.

These are company‑level signals drawn from Palisade’s filings and public releases; they describe the operating model rather than an isolated supplier metric. If you want the operational map visualized for diligence, visit https://nullexposure.com/ for our supplier intelligence tools.

Roll call — every relationship listed in the public record and what it means for risk

Below are every relationship entry in the supplied results, each summarized in plain English with the public source noted.

Giiant — FY2024 10‑K
Palisade discloses a license agreement with Giiant that creates a contingent consideration obligation tied to milestone payments, adding potential future liabilities if development targets are met. This is recorded in the company’s FY2024 Form 10‑K and affects contingent liability modeling. (Source: Palisade Bio FY2024 Form 10‑K.)

JTC Team, LLC — GlobeNewswire release, January 16, 2026
JTC Team is listed as Palisade’s investor relations contact in a press release announcing abstract selections for IBD conferences, signaling an active IR engagement strategy. (Source: GlobeNewswire press release, January 16, 2026.)

JTC Team, LLC — GlobeNewswire release, January 29, 2026
The same IR firm is listed on a release announcing clinical advisory board appointments, reinforcing that outsourced IR/PR handles external communications for clinical news and KOL updates. (Source: GlobeNewswire press release, January 29, 2026.)

JTC Team, LLC — GlobeNewswire release, February 5, 2026 (Oppenheimer presentation)
JTC Team is again the investor contact for the announcement that Palisade would present at Oppenheimer’s healthcare conference, underscoring consistent use of third‑party IR across investor events. (Source: GlobeNewswire press release, February 5, 2026.)

JTC Team, LLC — GlobeNewswire duplicate release, February 5, 2026
A second distribution of the Oppenheimer presentation notice lists the same IR contact; the duplication highlights broad press distribution strategy rather than new counterparty risk. (Source: GlobeNewswire press release distributed February 5, 2026.)

JTC Team, LLC — GlobeNewswire release, February 9, 2026 (Piper Sandler symposium)
JTC Team is again the contact for a release about Palisade participating in a Piper Sandler virtual symposium, indicating IR continuity across multiple investor conferences. (Source: GlobeNewswire press release, February 9, 2026.)

JTC Team, LLC — GlobeNewswire duplicate release, February 9, 2026
Another version of the February 9 distribution lists JTC Team, confirming syndication of the same investor message. (Source: GlobeNewswire press release, February 9, 2026.)

JTC Team, LLC — GlobeNewswire release, February 17, 2026 (new advisory board appointment)
JTC is again shown as the IR contact for a press release about an appointment to the clinical advisory board, reinforcing the company’s continued reliance on outsourced communications support. (Source: GlobeNewswire press release, February 17, 2026.)

GlobeNewswire via QuiverQuant — QuiverQuant article, March 2026
A third‑party aggregator reproduced a GlobeNewswire press release about Phase 1b data and appended an AI‑generated summary disclaimer, so investors should prefer the original press release for primary economic and clinical detail. (Source: QuiverQuant copy of GlobeNewswire release, March 2026.)

JTC Team, LLC via QuiverQuant — QuiverQuant article, March 2026
The same IR contact appears in the aggregator copy of the Phase 1b data announcement, again showing how Palisade’s external communications are circulated through both primary and secondary channels. (Source: QuiverQuant article reproducing GlobeNewswire, March 2026.)

Piper Sandler — GlobeNewswire release, February 9, 2026
Piper Sandler hosted Palisade management in a virtual fireside chat, an investor‑relations event that indicates engagement with the sell‑side and active investor roadshow activity. (Source: GlobeNewswire press release, February 9, 2026.)

Constraints and what they imply for diligence and valuation

The filing and disclosures produce clear constraints that should be woven into investment models and operational diligence:

  • Contracting posture — fully outsourced manufacturing and clinical services. Palisade does not intend to establish internal manufacturing and relies on CDMOs/CMOs and CROs for development and trials, which increases supplier dependence and operational execution risk. (Company filing signals.)
  • Geographic concentration — APAC sourcing for API. The company maintains agreements with third parties in China and other countries for API supply; this creates geopolitical and logistics exposure that must be stress‑tested in scenario analysis. (Company filing signals.)
  • Materiality of supply — API availability is a business risk. The company states that insufficient API or raw materials could adversely impact operations, making supply resilience and backup sourcing critical to commercial timing. (Company filing signals.)
  • Service provider spend — mid six‑figure professional fees. Financial disclosure shows $454,213 of fees billed by an independent accounting firm in 2024, which anchors a spend band in the low‑to‑mid six‑figure range for key external suppliers. (Company filing signals.)
  • Lifecycle stage — active clinical sourcing and CRO oversight. Palisade has retained CROs for Phase 1 trials and lists active supplier relationships, indicating that supplier risk is immediate and operational rather than prospective. (Company filing signals.)

Investment implications and recommended next steps

Palisade’s path to value is execution‑dependent: clinical data, supply continuity and the management of contingent obligations (such as the Giiant milestone payments) are the drivers of equity upside or downside. For investor and operator diligence prioritize:

  • Counterparty audits of primary CDMOs for API lead times and alternative supply options.
  • Modeling contingent liabilities into downside scenarios, including the milestone structure cited in the FY2024 filing.
  • Verification of IR/PR flows to ensure primary releases (GlobeNewswire) are not being obscured by secondary aggregators with AI disclaimers.

If you want an operational supplier map and financial stress tests built to these specifics, see our coverage and tools at Null Exposure: https://nullexposure.com/

Final takeaways

  • Palisade is a clinical‑stage, outsourced operator whose value depends on timely third‑party manufacturing, CRO execution and successful clinical readouts.
  • Contingent obligation to Giiant and APAC API sourcing are material risk vectors that should be reflected in downside scenarios.
  • Outsourced IR is active and consistent; primary sources such as GlobeNewswire are the place to confirm clinical and investor events.

For a tailored supplier risk briefing on Palisade or comparable clinical‑stage biotechs, start here: https://nullexposure.com/ — our team maps counterparty exposure to help you underwrite execution risk.